




- (51) **International Patent Classification:**  
A01N 43/38 (2006.01) A61K 31/40 (2006.01)
- (21) **International Application Number:**  
PCT/US2010/053916
- (22) **International Filing Date:**  
25 October 2010 (25.10.2010)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
61/254,395 23 October 2009 (23.10.2009) US
- (71) **Applicants (for all designated States except US):**  
**HEALTH RESEARCH INC.** [US/US]; Elm And Carlton Streets, Buffalo, NY 14263 (US). **CLEVELAND BIOLABS, INC.** [US/US]; 73 High Street, Buffalo, New York 14203 (US).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** **GUROVA, Katerina** [RU/US]; 61 Graystone Lane, Orchard Park, NY 14127 (US). **NARIZHEVA, Natalia** [RU/US]; 100 North Lake Drive #15, Orchard Park, NY 14127 (US).
- (74) **Agents:** **LOPINSKI, John, D.** et al.; The Guaranty Building, 140 Pearl Street, Suite 100, Buffalo, NY 14202-4040 (US).
- (81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,

[Continued on next page]

(54) **Title:** METHOD FOR TREATING ANDROGEN RECEPTOR POSITIVE CANCERS

Figure 10

**CLASS 54 (c52)**

(57) **Abstract:** Provided is a method of inhibiting growth of androgen receptor positive cancer cells. The method entails administering to an individual diagnosed with or suspected of having an androgen receptor positive cancer and administering to the individual a composition containing a compound that can inhibit the growth of the androgen receptor positive cancer.



TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, **Published:**

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,

LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,

GW, ML, MR, NE, SN, TD, TG).

— *with international search report (Art. 21(3))*